ARS Pharmaceuticals Inc.

SPRY | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.35

+$0.24 (+5.84%)

At close: Sep 21, 2026, 4:00 PM ET

$4.35

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+5.84%

(1D)

Rating

Updated: Aug 17, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $431.97M

1D Range

4.12 4.39

52W Range

4.07 13.15

Valuation (TTM)

PE -2

PB 34.52

EV/EBITDA -1.38

Valuation (NTM)

Forward PE N/A

Forward PEG 0.03

Price Target $20

Cash Flow

FCF Yield -45.5%

SBC Adj. FCF Yield -52.8%

SBC Impact -15.9%

Margins

Gross Margin 73.9%

Operating Margin -185.0%

FCF Margin -168.1%

Growth (CAGR)

Revenue 3Y | 5Y 711.3% | 94.3%

Dil EPS 3Y | 5Y -81.4% | -40.2%

FCF 3Y | 5Y -77.7% | -34.7%

Returns

ROA -86.3%

ROE -256.7%

ROIC -114.6%

Financial Health

Net Cash

$143.85M

Current Ratio 3.48

Interest Coverage -43.96

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individu...

Sector Healthcare

Industry Biotechnology

Employees 195

IPO Date Dec 3, 2020

Website ars-pharma.com

Fiscal Year January - December

Full Company Profile

Latest News

3 months ago · benzinga.com

ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) on Wednesday reaffirmed its expectation to achieve cash-flow breakeven in 2027, even as no additional commercial formulary decisions for its epinephrine nasal spray Neffy were secured during the July 1, 2026 coverage cycle.

3 months ago · investors.com

ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January

ARS Pharmaceuticals stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray, Neffy, to its formulary.

3 months ago · globenewswire.com

ARS Pharmaceuticals Provides Commercial and Financial Updates

No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion

Earnings

Next Earnings

Nov 9, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$20

Upside

+359.77%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞